Orexo Acquires Exclusive US Rights to Commercialize deprexis - IndiaMedToday
District Court of Delaware rules that Actavis does not infringes with their Suboxone® and Subutex® generics
Orexo enters patent infringement litigation against Actavis
Teva, denying 'any liability,' set aside $646M for opioid settlements. Here's why | Fierce Pharma
Orexo launches digital therapies for depression, alcohol misuse early in US | pharmaphorum
Orexo seeks approval of nasal high-dose opioid rescue medicine
Teva extends global rebrand with tailored marketing messages for caregivers | Fierce Pharma
Teva kept quiet for weeks on forthcoming generics blow: report | Fierce Pharma
Full Year Report incl. Q4 2017
Opioid Use Disorder Market Growth to register a CAGR of 8.7% to reach USD US$ 4,911.8 Million by 2028 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, | Medgadget
Cancer Pain Diagnostics Market 2022 Structure with Top Industry
In opioid case, NY wants to probe Teva's control of Teva USA
OREXO AB (PUBL)
Orexo sues Actavis and Teva over narcotic dependency treatment
Fast-dissolving opioid dependence tablet wins EU recommendation - Drug Delivery Business
Annual Report
Domstol afviser omhøring af patentsag mellem Teva og Novo-firmaet Orexo — MedWatch
Suboxone sales down as opioid addiction drug market intensifies
Orexo misses out on millions after losing patent infringement suit against Actavis
Orexo
Annual Report
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OREXO AB and OREXO US, INC., Plaintiffs, ACTA VIS ELIZABETH LLC
Swedish Pharmaceutical Company: Orexo soars after winning opioid drug appeal against Teva, Health News, ET HealthWorld
Type headline here
